WHO WE ARE
The company was founded by two researchers, Joana Simões Correia and Ricardo Neves and one manager, Luísa Marques. The project that led to the creation of the company (Nanoinspire) participated in COHiTEC 2014 program and is the result of the research developed in collaboration between the Centre for Neurosciences and Cellular Biology of Coimbra University, Crioestaminal SA, and Biocant. Founded in June 2015, the company has so far secured €1M funding, of which €900K from venture capital firms, and in excess of €600K from a Portugal 2020 R&D grant.
Exo-T received the Young Entrepreneur Award by ANJE in 2015, and the Everis Award in 2016. In the same year, the company obtained the SME Instrument Phase 1 support from the European Commission, and in 2017 the company was a finalist of the Alira Health - EWMA (European Wound Management Association) Award, recognizing Exo-T as one of the top 5 most Innovative Companies worldwide in wound care.
Joana Simões Correia
Board and Advisors
Exogenus’ Scientic Officer speaker at World Advanced Therapies and Regenerative Medicine Congress 2019
Joana Correia, founder, Executive Director and Chief Scientific Officer of Exogenus Therapeutics will be presenting at the 14th World Advanced Therapies and Regenerative Medicine Congress taking place 15th to 17th of May in London. Joana will be presenting Exogenus’s experience on the specific case of umbilical cord blood derived exosomes and its therapeutic potential at Read more about Exogenus’ Scientic Officer speaker at World Advanced Therapies and Regenerative Medicine Congress 2019[…]
Exogenus Therapeutics is the winner of the 2nd edition of Prémio Empreendedor XXI, Portugal – North and Central Regions. This prize is organized by BPI and DayOne, a division of CaixaBank specialized in technological companies, in partnership with Agência Nacional de Inovação and the Alto Patrocínio do Ministério da Economia. Exogenus Therapeutics was selected among Read more about Exogenus Therapeutics wins Prémio Empreendedor XXI 2018[…]
Exogenus is amongst the 500 deeptech startups running for the Hello Tomorrow Global Challenge. The Hello Tomorrow Global Challenge is a worldwide renowned science & technology startup competition designed specifically to address the needs of deeptech entrepreneurs across several different industries and technologies. Finalists will be announced in January 2019 and the Global Summit will take place in Read more about Exogenus Therapeutics on the Top 500 deeptech startups shortlist of Hello Tommorrow[…]
Exogenus Therapeutics é uma start-up de base tecnológica dedicada ao desenvolvimento de terapias inovadoras. Com uma equipa jovem e dinâmica localizada no parque biotecnológico de Cantanhede (Biocant Park), pretende recrutar um estagiário para estágio IEFP para apoiar a atividade administrativa e financeira fazendo a ponte entre a Direção e os serviços de Contabilidade, com Read more about Estamos a recrutar um Estagiário(a) Adminstrativo(a)[…]
We are glad to announce that Graça Raposo, one of the first scientists worldwide who recognized the biological role of Extracellular Vesicles (EVs) in human biology, has joined our Advisory Board. Commonly referred within experts as “the mother of exosomes”, Graça Raposo has been extensively recognized in the field, and received many distinctions such as the CNRS Read more about Graça Raposo joins Exogenus Therapeutics Advisory Board[…]
Exogenus is presenting a poster at ISEV 2018 Annual meeting taking place in Barcelona between 2-6 May. With over 1,000 attendees, ISEV2018 gathers experts and researchers on extracellular vesicle research, covering the latest progresses in exosomes, microvesicles. Exogenus is one of the few companies worldwide developing EV-based therapeutics. Silvia Rodrigues is presenting a poster on “Development Read more about Exogenus presents poster at ISEV 2018 Annual meeting[…]
Exogenus is developing promising therapeutics for the treatment of chronic and acute wounds, among which are diabetic foot ulcers, some of the most debilitating and hard-to-heal. The lead technology licensed and under development by Exogenus for the treatment of wounds, is owned by Crioestaminal and Biocant, and relates to the use of exosomes secreted by Read more about Technology licensed by Exogenus presented at 14th Portuguese Congress of Diabetes[…]
Silvia Rodrigues, PhD student at Exogenus Therapeutics, presented a poster with results on research and development work done on the automatization of cord blood processing for production of an exosome-based medicinal product and its relevance for the scaling up of clinical-grade manufacturing process. Held in Coimbra in February 2018, the 1st Meeting on Vesicular Biology of Read more about Exogenus present at 1st Meeting on Vesicular Biology[…]
Exogenus was recognized at BioEurope 2017, one of the biggest biotech industry events! Listen to Joana Simões Correia on Exogenus Therapeutics: Event organizers, EBD Group and Johnson & Johnson Innovation, recognized how hard a task it was to choose the winner at this edition. https://labiotech.eu/startup-slam-bio-europe-2017-winner/
Exogenus was one of the 20 biotech startups selected to participate at Bio Europe 2017 Startup Slam taking place on November 7th in Berlin. Participants will have the chance to present in front of a jury of investors, dealmakers and biotech KOL’s. Check out Labiotech’s article on the event. Joana Correia said: “Bio Europe Startup Slam is Read more about Exogenus Therapeutics – one of the hottest startups of 2017![…]